CODXCODXHealthcare · Medical Devices

CODX Stock Forecast: Co-Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.13
−22.11% on the day

The median 12-month analyst price target for Co-Diagnostics, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.7M
Ticker Nerd rank
32/ 100
Median analyst target
$4.00
Analysts covering
1
Revenue$166K+2.0% y/y
Operating income−$6.2M
Net income−$6.3M
Free cash flow−$7.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−50.5%
1M
−80.2%
YTD
−97.5%
1Y
−98.7%
From 52W high
−98.9%
From 52W low
0.0%
$0
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Co-Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
32/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Growth
83
Revisions
57
Issuance
15
Value
10
Quality
6
Volatility
5
Momentum
4

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CODX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CODX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26CODXHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$4.00
Low
$4.00
Median
$4.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Jan 2026Maxim GroupDowngradeHold—
26 Nov 2025Maxim GroupInitiatesBuy—
24 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
28 Oct 2025D. Boral CapitalMaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
17 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
12 Aug 2024HC Wainwright & Co.MaintainsNeutral—
17 June 2024HC Wainwright & Co.ReiteratesNeutral—
13 May 2024HC Wainwright & Co.MaintainsNeutral—
15 Mar 2024HC Wainwright & Co.MaintainsNeutral—
29 Dec 2023HC Wainwright & Co.ReiteratesNeutral—
13 Nov 2023HC Wainwright & Co.MaintainsNeutral—
14 Aug 2023HC Wainwright & Co.MaintainsNeutral—
15 May 2023HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CODX.

Market Radar

This page is one stock. Monday covers all of them.

CODX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CODX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Co-Diagnostics, Inc. returned −98.7% against +6.9% for the S&P 500, dividends included.

CODX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26CODXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CODX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.7×

Cheaper than 53% of US stocks

Price / book
0.1×

Cheaper than 96% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−192.8%

Higher than 8% of US stocks

Return on assets
−63.7%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Co-Diagnostics, Inc. has a market value of $1.7M and an enterprise value of $2.6M.

  • Revenue in the twelve months to 30 June 2026: $721K. The latest quarter grew 2.0% year on year.

  • Net income over the same four quarters: −$47.1M, a −6523.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$27.5M.

  • Shares outstanding: 4.9M.

  • Co-Diagnostics, Inc. employs 115 people — $6K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CODX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CODXCo-Diagnostics, Inc.$1.7M32
NXLNexalin Technology, Inc.$1.7M24
ADGMAdagio Medical Holdings, Inc.$1.7M24
GCTKGlucoTrack, Inc.$1.6M—
AMIXAutonomix Medical, Inc.$1.7M31
VVOSVivos Therapeutics, Inc.$1.8M43
PFSAProfusa, Inc.$1.8M19

Take a look at CODX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Co-Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CODX

What is the CODX stock price forecast for 2026-2027?

The median 12-month analyst price target for Co-Diagnostics, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CODX stock a buy right now?

Of the 1 analyst covering Co-Diagnostics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Co-Diagnostics, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CODX?

As at 21 Nov 2026, Co-Diagnostics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will CODX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $4, and Ticker Nerd's factor model ranks Co-Diagnostics, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CODX stock forecast for 2030?

No analyst covering Co-Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CODX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has CODX stock performed over the past year?

Co-Diagnostics, Inc. returned -98.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Co-Diagnostics, Inc. do?

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications. Co-Diagnostics focuses on PCR-based solutions, including the Co-Dx PCR platform for point-of-care and at-home testing, as well as diagnostic tests for conditions such as COVID-19, influenza, tuberculosis, hepatitis, malaria, dengue, and other pathogens.

Company

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications. Co-Diagnostics focuses on PCR-based solutions, including the Co-Dx PCR platform for point-of-care and at-home testing, as well as diagnostic tests for conditions such as COVID-19, influenza, tuberculosis, hepatitis, malaria, dengue, and other pathogens. The company also develops molecular tools for mosquito testing, agricultural pathogen detection, and genetic analysis in plant and animal genomes. Its proprietary Co-Primers technology is designed to support highly specific test development and simplify complex molecular testing workflows. Headquartered in Salt Lake City, Utah, Co-Diagnostics serves healthcare, public health, research, and agricultural markets through its diagnostics products and development platforms.

CEO Mr. Dwight H. Egan · 115 employees · United States · https://co-dx.com